ArticleBMC cancer2026
Dose-effect relationship of D90 in iodine-125 seed implantation for advanced lung cancer: gradient-based efficacy and survival outcome.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeThis study aimed to evaluate the dose–response relationship and survival outcomes of iodine-125 seed implantation in patients with advanced lung cancer, focusing on the impact of different dose levels on tumor control and patient prognosis.
methodsA retrospective analysis was conducted on 49 patients with advanced lung cancer who underwent iodine-125 seed implantation between January 2017 and March 2021. The patients were divided based on postoperative D90 dose levels, and tumor control rates, including complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD), were assessed. The objective response rate (ORR) and disease control rate (DCR) were also evaluated. Survival analysis was performed to identify prognostic factors.
resultsThe optimal D90 cutoff values for CR, ORR, and DCR were 136.46 Gy, 121.98 Gy, and 111.47 Gy, respectively. Higher D90 doses were significantly associated with improved tumor control rates (P < 0.05). The 3-year survival rate was 20.41%, with complete response (CR) and preoperative hemoglobin levels identified as independent prognostic factors for long-term survival.
conclusionIodine-125 seed implantation demonstrates a clear dose–response relationship in advanced lung cancer, with higher D90 doses correlating with better tumor control. CR and hemoglobin levels are critical factors influencing long-term survival outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.